Transcription of PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 …
{{id}} {{{paragraph}}}
Example: barber
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 …
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS. AND RELEASES 5-YEAR PIPELINE METRICS. Upjohn Business(1) Now Accounted for as a Discontinued Operation for All Periods Presented, Excluded from Adjusted(2) Results FULL-YEAR 2020 Revenues of $ Billion, Which Now Exclude Upjohn(1), Reflect 3% Operational Growth;. When the Impact from Consumer Healthcare(1) and the $154 Million of Sales of BNT162b2 are Excluded, FULL-YEAR 2020 Revenues Grew 8% Operationally Operational Growth Primarily Driven by Strong Performances from Vyndaqel/Vyndamax, Eliquis, Oncology Biosimilars, Ibrance, Prevenar 13 Outside of the , Inlyta, Xeljanz and Xtandi FOURTH-QUARTER 2020 Revenues of $ Billion, Reflecting 11% Operational Growth; Excluding Sales of BNT162b2, Revenues Grew 9% Operationally FULL-YEAR 2020 Reported Diluted EPS(3) of $ , Adjusted Diluted EPS(2) of $ ; FOURTH-QUARTER 2020.
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2020 has been a transformational year, not only for Pfizer, but also in the life of every patient in every community that we serve. As a company, we saw the culmination of Pfizer’s decade-long conversion into a pure-play, science and innovation-focused company. Right
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: